As an alternative, we developed CBPD-409, a potent, orally bioavailable PROTAC degrader that selectively targets p300/CBP, exhibiting favorable pharmacokinetics and preferential cytotoxicity in AR-driven prostate cancer over normal prostate and other tumor types. This evidence concerns the gene AR and prostate cancer.